SCHEMBL6282679

SCHEMBL6282679

CC(Sc1nc2ccccc2n1C[C@H](C)O)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
GAA P10253 1/20 0.52
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 2/20 0.44
TP53 P04637 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285172 0.80 ALDH1A1 (0.67) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL6284250 0.80 ALDH1A1 (0.55) MAPTGAAALDH1A1LMNATP53
SCHEMBL6313465 0.76 MAPT (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL8360122 0.76 MAPT (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6276823 0.76 MAPT (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6279563 0.76 ALDH1A1 (0.51) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL6280071 0.74 NPC1 (0.59) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL6281551 0.71 PTGDR2 (0.64) MAPTCYP3A4CYP2C19
SCHEMBL6282492 0.69 MEN1 (0.50) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL6277488 0.69 AR (0.56) MAPTMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS MAPT 268/4885GAA 1377/4885ALDH1A1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.